Blood Test Boosts Lung Cancer Screening Participation
New clinical utility data showed that offering a blood-based lung cancer test increased screening participation compared with low-dose CT screening alone.
New clinical utility data showed that offering a blood-based lung cancer test increased screening participation compared with low-dose CT screening alone.
The test uses a new approach to identify signs of cancer recurrence with faster result times for healthcare providers and patients.
The new recommendations add blood-based testing and multi-target stool testing as options for average-risk adults starting at age 45.
The study identifies HAVCR1 as a tool for earlier detection and treatment monitoring for primary central nervous system lymphoma.
Co-Diagnostics has completed its assay development strategy for Bundibugyo virus, following the WHO’s emergency declaration and CDC’s updated traveler screening measures amid ongoing Ebola outbreaks in the DRC and Uganda.
AOA Dx presented data at AACR 2026 supporting its AKRIVIS GD Test System, a multi-omic, blood-based assay for early ovarian cancer detection in symptomatic women, reporting an AUC of 0.92 in clinical controls.
The Elecsys NfL test measures a protein associated with nerve cell injury to monitor disease activity in patients with relapsing remitting multiple sclerosis.
The new kit uses Tasso+ collection technology and certified laboratory analysis to monitor 17 health markers, including blood sugar and lipid levels.
The sensor identifies misfolded protein biomarkers in blood before clinical symptoms of neurodegeneration appear.
As diabetes testing evolves, labs are seeing growing interest in earlier screening, additional biomarkers, and tools that can support more preventive care.
Insight Molecular Diagnostics has completed clinical validation and received ISO 13485 certification for its GraftAssureDx kidney transplant rejection test kit, moving toward FDA submission, according to the company.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
VolitionRx reports its lateral flow prototype can detect nucleosomes in finger-prick blood samples from sepsis patients, enabling rapid, point-of-care testing outside centralized labs, according to company data.